Colorectal CancerNCT05740137
Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy
A study testing AI-assisted colonoscopy in people with Colorectal Cancer and Colorectal Adenoma, run by Ismail Gögenur at 4 sites in Denmark.
Trial summary
The goal of this quasi randomized multicenter controlled clinical trial (RCT) is to investigate whether a combined real time computer-aided polyp detection (CADe) and computer-aided polyp characterization (CADx) system (GI Genius, Medtronic) can increase the adenoma detection rate (ADR) and reduce the performance… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
- What is being tested?
- AI-assisted colonoscopy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 795 participants
- Where
- 4 sitesDenmark
- Study dates
- 1 Oct 2022to 3 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for
- Diagnostic colonoscopy due to symptoms/signs or
- Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy)
Who cannot join
- Referral for removal of previous detected polyps
- Emergency colonoscopy
- Control colonoscopy due to inflammatory bowel disease (IBD)
Trial locations and contacts
4 sites in 1 country.
Denmark4 sites
Holbæk Hospital
Holbæk, 4300
Zealand University Hospital
Køge, 4600
Næstved Hospital
Næstved, 4700
Nykøbing Falster County Hospital
Nykøbing Falster, 4800
About this study
Official title: Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy Performed by Endoscopists with Different Levels of Experience - a Quasi Randomized Controlled Multicenter Trial
The goal of this quasi randomized multicenter controlled clinical trial (RCT) is to investigate whether a combined real time computer-aided polyp detection (CADe) and computer-aided polyp characterization (CADx) system (GI Genius, Medtronic) can increase the adenoma detection rate (ADR) and reduce the performance variability among endoscopists.
Participants will be randomized (1:1) to either receive an AI-assisted colonoscopy (AIC) or a conventional colonoscopy (CC).
If there is a comparison group: Researchers will compare the AIC-group and the CC-group to see if AIC can increase the ADR significantly.
Read the detailed description
Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard.
Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy.
The adenoma detection rate (ADR) is the percentage of examinations performed by one endoscopist, in which one or more adenomas are found. This is widely accepted as the main quality indicator for each endoscopist and colonoscopy. There is strong evidence that the ADR is inversely correlated to the incidence of interval CRC. With each 1,0% increase in the ADR there is a 3,0% decrease in the risk of developing CRC. Unfortunately, adenomas and advanced adenomas are frequently missed, and the ADR varies widely among different endoscopists. Also, the quality changes throughout the day. Both the withdrawal time and the ADR decreases by the end of the day, approximately by 20% and 7% respectively. Small improvements in the colonoscopy quality may have great importance for the outcome when screening for CRC.
Artificial intelligence (AI) can reduce the performance variability by working as a pair of additional virtual eyes, compensating for perceptual errors due to fatigue, distraction and inaccurate human vision. Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Among these, all of the RCT´s which have ADR as the primary outcome, have shown that the use of AI contributes to a significantly higher ADR, compared colonoscopies without assistance of an AI system.
Repici et al. have shown that experience of the endoscopist only plays a minor role as a determining factor. Correspondingly, results from a previous study by Liu et al. indicates that CADe systems are not only useful for endoscopists with a low detection rate, but can also increase the ADR for more experienced endoscopists. Kamba et. al reports a significant lower adenoma miss rate (AMR) for CADe-assisted colonoscopy, compared to a conventional colonoscopy. This is independent on the endoscopist´s level of expertise. Other studies conclude that AI probably will benefit the less experienced endoscopists more. However, there are only a limited number of studies investigating the impact of AI when used by less experienced endoscopists.
According to a recent RCT from Wallace et al. the use of AI can reduce the AMR by approximately 50%, but primarily due to increased detection of small (\<10 mm) flat neoplasia. This difference is slightly higher than in a previous study, in which the relative reduction was approximately 35%. However, in this study there were no significant difference in missed diminutive polyps (\<10 mm).
In a systematic review the overall withdrawal time was shown to be higher with AI-assisted colonoscopy (AIC), compared to conventional colonoscopy (CC), but the ADR and PDR was also higher. Naturally, there have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI system, since the increased detection of small polyps may lead to unnecessary polypectomy. However, two recent RCT´s report that the unnecessary resection of non-neoplastic polyps did not increase by using the CADe system.
The results so far are promising, suggesting that AIC is superior to CC when it comes to polyp and adenoma detection. Routine use of computer-aided polyp detection (CADe) systems could further reduce the incidence of interval CRC, but more clinical data from large multicenter randomized trials are required to understand the actual impact of AI in the daily clinical setting.
We have designed a quality assurance multicenter quasi RCT to investigate the effect of real time AI-assistance (GI Genius, Medtronic) on adenoma detection rate (ADR) in both experienced and less experienced endoscopists. We want to investigate whether the CADe system can reduce the performance variability and increase the ADR significantly.
The overall aim of this research is to investigate if AI-assistance in colonoscopy can increase the ADR.
This prospective, multicenter, quasi randomized controlled trial (RCT) will take place at four endoscopy units in Region Zealand, Denmark. These units are located at Zealand University Hospital (Køge), Nykøbing Falster Hospital, Holbæk Hospital and Næstved Hospital. All units except Næstved Hospital are participating in the national CRC-screening programme.
We will screen all patients scheduled for screening, diagnostic, and surveillance colonoscopy. The eligible patients will receive a colonoscopy from an expert or a non-expert endoscopist based on the normal distribution of endoscopists at the endoscopic units.
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
- Being tested
- AI-assisted colonoscopy
- Keywords
- Artificial intelligence-assisted colonoscopy, Computer-aided polyp detection, Colorectal adenoma
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-assisted colonoscopyDevice
The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Conventional colonoscopy, without AI-assistance. |
| AI-assisted colonoscopy | Active comparator | AI-assisted colonoscopy (AIC) using a computer-aided polyp detection and characterization (CADe and CADx) system. Receives: Device: AI-assisted colonoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adenoma detection rate (ADR)
ADR = (number of examinations with adenomas/total number of examinations) × 100.
Measured: 5 Months
Secondary outcomes (6)
Polyp detection rate (PDR)
PDR = (number of examinations with polyps/total number of examinations) × 100.
Measured: 5 Months
Adenomas per colonoscopy (APC)
Number of adenomas found per procedure
Measured: 5 Months
Polyps per colonoscopy (PPC)
Number of polyps found during per procedure
Measured: 5 Months
Duration of the procedure
Duration of the colonoscopy
Measured: 5 Months
Non-neoplastic resection rate (NNRR)
Number of resected non-neoplastic polyps/total number of resected polyps
Measured: 5 Months
ADR in the CRC-screening population
Adenoma detection rate (ADR) in one of the patient subgroups
Measured: 5 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2023
- Study start1 Oct 2022
- Primary completion3 Mar 2023
- Study completion3 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A quasi randomized controlled multicenter study
- Masking
- None (open label)
- Enrolment
- 795 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ismail Gögenur
- Sponsor type
- University, hospital or other
- Collaborators
- Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital
- Responsible party
- Sponsor-investigator, Ismail Gögenur, Zealand University Hospital
- Investigators
- Ronja Lagström, MD, Principal investigator, Zealand University Hospital, Køge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05740137
- Sponsor's protocol ID
- REG-092-2022
- Status last verified
- Sep 2024
- First submitted
- 3 Feb 2023
- Last updated
- 6 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy Performed by Endoscopists with Different Levels of Experience - a Quasi Randomized Controlled Multicenter Trial
- ClinicalTrials.gov ID
- NCT05740137
- Acronym / sponsor ID
- REG-092-2022
- Conditions
- Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
- Keywords
- Artificial intelligence-assisted colonoscopy, Computer-aided polyp detection, Colorectal adenoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 795 participants (actual)
- Lead sponsor
- Ismail GögenurUniversity, hospital or other
- Collaborators
- Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital
- Study start
- 1 Oct 2022 (actual)
- Primary completion
- 3 Mar 2023 (actual)
- Study completion
- 3 Mar 2023 (actual)
- First posted
- 22 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this quasi randomized multicenter controlled clinical trial (RCT) is to investigate whether a combined real time computer-aided polyp detection (CADe) and computer-aided polyp characterization (CADx) system (GI Genius, Medtronic) can increase the adenoma detection rate (ADR) and reduce the performance variability among endoscopists.
Participants will be randomized (1:1) to either receive an AI-assisted colonoscopy (AIC) or a conventional colonoscopy (CC).
If there is a comparison group: Researchers will compare the AIC-group and the CC-group to see if AIC can increase the ADR significantly.
Detailed description
Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard.
Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy.
The adenoma detection rate (ADR) is the percentage of examinations performed by one endoscopist, in which one or more adenomas are found. This is widely accepted as the main quality indicator for each endoscopist and colonoscopy. There is strong evidence that the ADR is inversely correlated to the incidence of interval CRC. With each 1,0% increase in the ADR there is a 3,0% decrease in the risk of developing CRC. Unfortunately, adenomas and advanced adenomas are frequently missed, and the ADR varies widely among different endoscopists. Also, the quality changes throughout the day. Both the withdrawal time and the ADR decreases by the end of the day, approximately by 20% and 7% respectively. Small improvements in the colonoscopy quality may have great importance for the outcome when screening for CRC.
Artificial intelligence (AI) can reduce the performance variability by working as a pair of additional virtual eyes, compensating for perceptual errors due to fatigue, distraction and inaccurate human vision. Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Among these, all of the RCT´s which have ADR as the primary outcome, have shown that the use of AI contributes to a significantly higher ADR, compared colonoscopies without assistance of an AI system.
Repici et al. have shown that experience of the endoscopist only plays a minor role as a determining factor. Correspondingly, results from a previous study by Liu et al. indicates that CADe systems are not only useful for endoscopists with a low detection rate, but can also increase the ADR for more experienced endoscopists. Kamba et. al reports a significant lower adenoma miss rate (AMR) for CADe-assisted colonoscopy, compared to a conventional colonoscopy. This is independent on the endoscopist´s level of expertise. Other studies conclude that AI probably will benefit the less experienced endoscopists more. However, there are only a limited number of studies investigating the impact of AI when used by less experienced endoscopists.
According to a recent RCT from Wallace et al. the use of AI can reduce the AMR by approximately 50%, but primarily due to increased detection of small (\<10 mm) flat neoplasia. This difference is slightly higher than in a previous study, in which the relative reduction was approximately 35%. However, in this study there were no significant difference in missed diminutive polyps (\<10 mm).
In a systematic review the overall withdrawal time was shown to be higher with AI-assisted colonoscopy (AIC), compared to conventional colonoscopy (CC), but the ADR and PDR was also higher. Naturally, there have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI system, since the increased detection of small polyps may lead to unnecessary polypectomy. However, two recent RCT´s report that the unnecessary resection of non-neoplastic polyps did not increase by using the CADe system.
The results so far are promising, suggesting that AIC is superior to CC when it comes to polyp and adenoma detection. Routine use of computer-aided polyp detection (CADe) systems could further reduce the incidence of interval CRC, but more clinical data from large multicenter randomized trials are required to understand the actual impact of AI in the daily clinical setting.
We have designed a quality assurance multicenter quasi RCT to investigate the effect of real time AI-assistance (GI Genius, Medtronic) on adenoma detection rate (ADR) in both experienced and less experienced endoscopists. We want to investigate whether the CADe system can reduce the performance variability and increase the ADR significantly.
The overall aim of this research is to investigate if AI-assistance in colonoscopy can increase the ADR.
This prospective, multicenter, quasi randomized controlled trial (RCT) will take place at four endoscopy units in Region Zealand, Denmark. These units are located at Zealand University Hospital (Køge), Nykøbing Falster Hospital, Holbæk Hospital and Næstved Hospital. All units except Næstved Hospital are participating in the national CRC-screening programme.
We will screen all patients scheduled for screening, diagnostic, and surveillance colonoscopy. The eligible patients will receive a colonoscopy from an expert or a non-expert endoscopist based on the normal distribution of endoscopists at the endoscopic units.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- A quasi randomized controlled multicenter study
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Conventional colonoscopy, without AI-assistance. |
| AI-assisted colonoscopy | Active comparator | Device: AI-assisted colonoscopyAI-assisted colonoscopy (AIC) using a computer-aided polyp detection and characterization (CADe and CADx) system. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for
- Diagnostic colonoscopy due to symptoms/signs or
- Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy)
Key exclusion criteria (3 listed)
- Referral for removal of previous detected polyps
- Emergency colonoscopy
- Control colonoscopy due to inflammatory bowel disease (IBD)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-assisted colonoscopyThe patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic). | Device | AI-assisted colonoscopy |
Primary outcome
Adenoma detection rate (ADR)
Time frame: 5 Months
ADR = (number of examinations with adenomas/total number of examinations) × 100.
6 secondary outcomes
Polyp detection rate (PDR)
Time frame: 5 Months
Adenomas per colonoscopy (APC)
Time frame: 5 Months
Polyps per colonoscopy (PPC)
Time frame: 5 Months
Duration of the procedure
Time frame: 5 Months
Non-neoplastic resection rate (NNRR)
Time frame: 5 Months
ADR in the CRC-screening population
Time frame: 5 Months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2025.
Related trials for Colorectal Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
Active, not recruitingObservational study
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
Prostate Cancer, BRCA Mutation
RecruitingObservational study
ABCSG R07 Rectal Cancer Registry
Rectal Cancer, Adenocarcinoma of Rectum
Recruiting
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Cancer, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ronja Lagström, MD principal investigator
Zealand University Hospital, Køge
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-assisted colonoscopy in people with Colorectal Cancer and Colorectal Adenoma, run by Ismail Gögenur at 4 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adenoma detection rate (ADR) (time frame: 5 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2025.